NCT07037394 - A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

April 21, 2025

Study Completion Date

April 30, 2025

Conditions

Overt Hepatic Encephalopathy

Interventions

DRUG

Probiotic plus lactulose

Probiotic and lactulose will be administered per the dose and schedule specified in the arms.

DRUG

Rifaximin plus lactulose

Rifaximin and lactulose will be administered per the dose and schedule specified in the arms.

DRUG

L-ornithine-L-aspartate plus latulose

LOLA and lactulose will be administered per the dose and schedule specified in the arms.

DRUG

Lactulose

Lactulose will be administered per the dose and schedule specified in the arms.

Trial Locations (1)

Bahawal Victoria Hospital, Bahawalpur

All Listed Sponsors

lead

Qurratul Ain Jamil

OTHER